UNSPSC 51385000: Nonsteroidal anti inflammatory pyrroles

Nonsteroidal anti inflammatory drugs made from Azoles of one nitrogen and two double bonds that have aromatic chemical properties.

UNSPSC 51385000 Nonsteroidal anti-inflammatory pyrroles is a Class code with little recent activity directly matching its nominal scope; state and local opportunities tagged under this code center instead on emergency-response pharmaceuticals, wholesale generic-drug distribution, and direct-to-manufacturer pharmacy programs rather than pyrrole-class anti-inflammatory agents. The mismatch suggests either data-entry error in the source or that issuing bodies are using this code as a catch-all for pharmaceutical procurement without strict therapeutic classification. Where opportunities do appear under the code, they span emergency management agencies seeking naloxone and deactivation systems, state health departments purchasing generic multi-source drugs through cooperative vehicles, and health and human services commissions exploring direct-manufacturing relationships to reduce intermediaries and cost.

The three recent opportunities reflect geographically scattered activity across Florida, Texas, and Minnesota through diverse issuing bodies. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract execution targeted for July 1, 2026. The MMCAP solicitation requires submission through the ePro procurement system, compliance with cGMP and Drug Supply Chain Security Act standards, maintenance of relationships with at least two of three authorized wholesalers, and a 3 percent administrative fee on all contract purchases.